Yang Yang, PhD
Associate Professor of Obstetrics, Gynecology and Reproductive SciencesDownloadHi-Res Photo
Cards
Appointments
Contact Info
About
Copy Link
Titles
Associate Professor of Obstetrics, Gynecology and Reproductive Sciences
Biography
Ph.D., Microbiology, Nankai University, China.
Postdoctoral training, Tumor Biology, Yale University.
Last Updated on May 18, 2025.
Appointments
Obstetrics, Gynecology & Reproductive Sciences
Associate Professor on TermPrimary
Other Departments & Organizations
Education & Training
- PhD
- Nankai University (2009)
Research
Copy Link
Overview
Tumor initiation; Chemoresistance
Medical Research Interests
Ovarian Neoplasms
ORCID
0000-0002-0522-9053
Research at a Glance
Yale Co-Authors
Frequent collaborators of Yang Yang's published research.
Publications Timeline
A big-picture view of Yang Yang's research output by year.
Research Interests
Research topics Yang Yang is interested in exploring.
Alessandro Santin, MD
Stefania Bellone, PhD
Blair McNamara, MD
Cem Demirkiran, MD
Elena Ratner, MD, MBA
Mitchell Clark, MD, MPH
67Publications
2,350Citations
Ovarian Neoplasms
Publications
2025
Antibody Generation Using Cancer‐Derived Small Extracellular Vesicles (sEVs): A Platform for Targeted Cancer Therapy and Potential Personalized Applications
Firouzi M, Kang C, Ren X, Jung W, Abushukair H, Hartwich T, Ramesh R, Yoon J, Yang‐Hartwich Y, Oh T, Kim D. Antibody Generation Using Cancer‐Derived Small Extracellular Vesicles (sEVs): A Platform for Targeted Cancer Therapy and Potential Personalized Applications. Small 2025, e06918. PMID: 41311345, DOI: 10.1002/smll.202506918.Peer-Reviewed Original ResearchAltmetricConceptsTargeted cancer therapySmall extracellular vesiclesOVCAR-8Cancer therapyCancer-derived small extracellular vesiclesHuman ovarian carcinoma cell linesOvarian carcinoma cell linesCancer cell-specific targetingTumor-bearing miceTumor-targeting monoclonal antibodiesTumor-targeted therapyExtracellular vesiclesOVCAR-8 cellsCell-specific targetingCarcinoma cell linesEffective targeting ligandCancer-derivedSolid tumorsImmune activationNon-targeting controlPreclinical studiesTumor growthTumor accumulationPersonalized oncologyImmune responseIDR-induced CAR condensation improves the cytotoxicity of CAR-Ts against low-antigen cancers
Zhang X, Xiao Q, Zeng L, Hashmi F, Sato K, Hartwich T, Mansolf M, Yang-Hartwich Y, Su X. IDR-induced CAR condensation improves the cytotoxicity of CAR-Ts against low-antigen cancers. Nature Chemical Biology 2025, 1-13. PMID: 41023404, DOI: 10.1038/s41589-025-02031-x.Peer-Reviewed Original ResearchCitationsAltmetricConceptsCAR-TChimeric antigen receptor (CAR)-T cell therapyCAR-T therapyCancer cells in vitroRelease of cytotoxic factorsCAR-T functionSolid tumor modelsAbsence of antigenLow antigen expressionCells in vitroMembrane-proximal signalingAntigen expressionAntigen sensitizationAntitumor effectCell therapyTumor modelIntractable cancerCytotoxic factorKilling activityBlood cancerCancerCancer targetLow antigenicityTherapyEfficacyPreclinical Efficacy of the Estrogen Receptor Degrader Fulvestrant in Combination with RAF/MEK Clamp Avutometinib and FAK Inhibitor in a Low-Grade Serous Ovarian Cancer Animal Model with Acquired Resistance to Chemotherapy and Aromatase Inhibitor
Demirkiran C, Bellone S, Ettorre V, Mansolf M, Hartwich T, McNamara B, Greenman M, Yang-Hartwich Y, Ratner E, Santin N, Sethi N, Palmieri L, Coma S, Pachter J, Ottum S, Santin A. Preclinical Efficacy of the Estrogen Receptor Degrader Fulvestrant in Combination with RAF/MEK Clamp Avutometinib and FAK Inhibitor in a Low-Grade Serous Ovarian Cancer Animal Model with Acquired Resistance to Chemotherapy and Aromatase Inhibitor. International Journal Of Molecular Sciences 2025, 26: 8924. PMID: 41009492, PMCID: PMC12469703, DOI: 10.3390/ijms26188924.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsMeSH KeywordsAnimalsAntineoplastic Combined Chemotherapy ProtocolsAromatase InhibitorsCell Line, TumorDisease Models, AnimalDrug Resistance, NeoplasmFemaleFocal Adhesion Kinase 1FulvestrantHumansMiceMice, SCIDOvarian NeoplasmsProtein Kinase InhibitorsReceptors, EstrogenXenograft Model Antitumor AssaysConceptsPatient-derived tumor xenograftTriple combinationFocal adhesion kinasePreclinical efficacyAromatase inhibitorsClinical evaluationEstrogen receptor (ER)-positiveAcquired resistance to chemotherapyOvarian cancer animal modelEstrogen receptor degrader fulvestrantPatients wild-typeVS-4718Cancer animal modelTumor growth inhibitionLimited treatment optionsResistance to chemotherapyP-ERK levelsFocal adhesion kinase inhibitorMedian survivalRare tumorOvarian carcinomaRecurrence rateTumor xenograftsTreatment optionsFulvestrantIn vitro and in vivo activity of datopotamab deruxtecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in uterine and ovarian carcinosarcoma
Greenman M, Hartwich T, Demirkiran C, Bellone S, McNamara B, Yang Y, Altwerger G, Ratner E, Clark M, Papatla K, Azodi M, Dottino P, Schwartz P, Santin A. In vitro and in vivo activity of datopotamab deruxtecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in uterine and ovarian carcinosarcoma. Gynecologic Oncology 2025, 200: 318. DOI: 10.1016/j.ygyno.2025.04.452.Peer-Reviewed Original ResearchPreclinical efficacy of the estrogen receptor degrader fulvestrant in combination with RAF/MEK clamp avutometinib and FAK inhibitor in low-grade serous ovarian cancer with acquired resistance to chemotherapy and aromatase Inhibitor
Demirkiran C, Bellone S, Ettorre V, Hartwich T, Greenman M, McNamara B, Yang Y, Ratner E, Schwartz P, Coma S, Pachter J, Santin A. Preclinical efficacy of the estrogen receptor degrader fulvestrant in combination with RAF/MEK clamp avutometinib and FAK inhibitor in low-grade serous ovarian cancer with acquired resistance to chemotherapy and aromatase Inhibitor. Gynecologic Oncology 2025, 200: 315. DOI: 10.1016/j.ygyno.2025.04.448.Peer-Reviewed Original ResearchDatopotamab deruxtecan, a TROP2-directed antibody-drug conjugate, demonstrates antitumor activity in uterine serous carcinoma
Greenman M, Demirkiran C, Bellone S, Ettorre V, Hartwich T, McNamara B, Yang Y, Altwerger G, Ratner E, Clark M, Papatla K, Azodi M, Dottino P, Schwartz P, Santin A. Datopotamab deruxtecan, a TROP2-directed antibody-drug conjugate, demonstrates antitumor activity in uterine serous carcinoma. Gynecologic Oncology 2025, 200: 204. DOI: 10.1016/j.ygyno.2025.04.263.Peer-Reviewed Original ResearchDatopotamab deruxtecan, a novel TROP2-tareting antibody-drug conjugate with a topoisomerase I inhibitor payload, shows preclinical activity against primary and metastatic uterine and ovarian TROP2 over-expressing carcinosarcoma
Greenman M, Bellone S, Demirkiran C, Hartwich T, Ettorre V, McNamara B, Sethi N, Santin N, Palmieri L, Yang-Hartwich Y, Ratner E, Santin A. Datopotamab deruxtecan, a novel TROP2-tareting antibody-drug conjugate with a topoisomerase I inhibitor payload, shows preclinical activity against primary and metastatic uterine and ovarian TROP2 over-expressing carcinosarcoma. Gynecologic Oncology 2025, 199: 64-71. PMID: 40582040, DOI: 10.1016/j.ygyno.2025.06.017.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsCS cell linesPreclinical activityTROP2 expressionPresence of peripheral blood lymphocytesTopoisomerase I inhibitor payloadCell linesRare gynecologic tumorsChromium release assayResistance to chemotherapyTumor growth suppressionPeripheral blood lymphocytesIn vivoAntibody-drug conjugatesOvarian carcinosarcomaRecurrence rateGynecological tumorsNo significant differencePreclinical resultsHealthy donorsBlood lymphocytesPoor prognosisMouse xenograftsChromium releaseClinical trialsCell cytotoxicityPreclinical Activity of Datopotamab Deruxtecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2, in Uterine Serous Carcinoma.
Greenman M, Demirkiran C, Bellone S, Hartwich T, McNamara B, Ettorre V, Santin N, Sethi N, Yang-Hartwich Y, Papatla K, Ratner E, Santin A. Preclinical Activity of Datopotamab Deruxtecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2, in Uterine Serous Carcinoma. Cancer Research Communications 2025, 5: 774-782. PMID: 40299780, PMCID: PMC12062949, DOI: 10.1158/2767-9764.crc-25-0057.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsTrophoblast cell surface antigen 2Uterine serous carcinomaAntibody-dependent cell-mediated cytotoxicityAntibody-drug conjugatesCell-mediated cytotoxicitySerous carcinomaPreclinical activityCell linesTargets trophoblast cell-surface antigen-2Presence of peripheral blood lymphocytesTreatment of uterine serous carcinomaInduce antibody-dependent cell-mediated cytotoxicityPrimary USC cell linesRecurrent uterine serous carcinomaUSC xenograftsUterine serous carcinoma cell linesAntigen 2In vivoPrimary tumor cell linesTROP2 overexpressionBiomarker-targeted therapiesControl ADCChromium release assayHigher recurrence rateTumor growth suppressionImpacts of Obesity-Induced Insulin and Leptin Dysregulation on Ovarian Function and Fertility
Rodriguez Y, Yang-Hartwich Y, Perry R. Impacts of Obesity-Induced Insulin and Leptin Dysregulation on Ovarian Function and Fertility. Physiology 2025, 40: 1996. DOI: 10.1152/physiol.2025.40.s1.1996.Peer-Reviewed Original ResearchConceptsOvarian functionOvarian tissueObesogenic contextRestore ovarian functionOvarian cell functionsResponse to hormonal changesCell viabilityImpact reproductive healthChow-fed controlsHuman granulosa-like tumorGlucose uptakeImproving fertility outcomesPotential therapeutic interventionsLeptin dysregulationCell proliferation assayHFD-fed miceLeptin treatmentGranulosa cellsLeptin resistanceOvarian environmentOvarian cellsReduced cell viabilityHormonal dysregulationLeptin signalingInsulin treatmentSORL1-Mediated EGFR and FGFR4 Regulation Enhances Chemoresistance in Ovarian Cancer
Jiang Z, Bi F, Ge Z, Mansolf M, Hartwich T, Kolesnyk V, Yang K, Park W, Kim D, Grechukhina O, Hui P, Kim S, Yang-Hartwich Y. SORL1-Mediated EGFR and FGFR4 Regulation Enhances Chemoresistance in Ovarian Cancer. Cancers 2025, 17: 244. PMID: 39858026, PMCID: PMC11763764, DOI: 10.3390/cancers17020244.Peer-Reviewed Original ResearchCitationsConceptsEpidermal growth factor receptorOvarian cancerRecurrent tumorsSortilin-related receptor 1Therapeutic efficacy of carboplatinResistant to conventional chemotherapyResistant ovarian cancerMolecular mechanisms of chemoresistanceCancer models in vitroEfficacy of carboplatinRecurrent ovarian cancerOvarian cancer treatmentEffective targeted therapiesMechanisms of chemoresistancePro-tumor functionsGrowth factor receptorXenograft mouse modelConventional chemotherapyStabilization of epidermal growth factor receptorModel in vitroPro-tumorEnhanced chemoresistanceCarboplatin resistanceTherapeutic efficacyFactor receptor
Academic Achievements & Community Involvement
Copy Link
Honors
honor Department of Defense Ovarian Cancer Academy Award — Early-Career Investigator
08/01/2015National AwardDepartment of DefenseDetailsUnited Stateshonor Marsha Rivkin Ovarian Cancer Research Bridge Fund Award
06/01/2015International AwardMarsha Rivkin Ovarian Cancer Research CenterDetailsUnited Stateshonor American Association of Cancer Research Women in Cancer Research Scholar Award
04/14/2014International AwardAmerican Association of Cancer ResearchDetailsUnited Stateshonor Ovarian Cancer Research Ann Schreiber Program of Excellence Award
03/01/2014International AwardOvarian Cancer Research FundDetailsUnited States
News & Links
Copy Link
Media
News
- September 29, 2025
New Toolset by Yale Researchers Boosts Efficacy of CAR-T Cells Targeting Blood and Solid Cancers
- April 15, 2024
Genetic Analysis of Rare, Often Deadly Cervical Cancer Uncovers Potential Treatments
- April 01, 2024
Yale Cancer Center Experts, Scientists to Share Vision and Research at Leading Conference
- January 19, 2024Source: Yale Daily News
Yale scientists look to hearing loss to detect Alzheimer’s early
Get In Touch
Copy Link
Contacts
Locations
LSOG 205a
Academic Office
Farnam Memorial Building (330 Cedar)
330 Cedar Street
New Haven, CT 06510